Bosera HashKey Ether ETF Approved for Staking, Marking a New Milestone for Hong Kong's Virtual Asset Industry
HONG KONG, April 11, 2025 /PRNewswire/ -- Bosera International and HashKey Capital Limited today announced that the Bosera HashKey Virtual Asset Ether ETF (stock codes: 3009.HK/9009.HK), jointly launched by the two firms, has received official...
Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved
SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration...
Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer's Dementia
TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and Welfare as a...
Coway Holds 36th Annual General Meeting to Further Strengthen Shareholder Trust Through Sustainable Growth
Shareholders have rejected Align Partners' proposal for a cumulative voting system, reaffirming board independence Key agenda items, including the appointment of outside directors and the retirement of 650,000 treasury stocks to enhance shareholder...
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III...
Korea Zinc Announces AGM Results, with the Current Management Retaining Control of the Board with Overwhelming Shareholder Support
SEOUL, South Korea, March 28, 2025 /PRNewswire/ -- Korea Zinc (KRX:010130) announced on March 28 that it has successfully concluded its annual general meeting (AGM), with the current management retaining board control in contention against MBK and...
IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau
SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and...
Bulletin from the Annual General Meeting of AB Electrolux
The Annual General Meeting of AB Electrolux was held in Stockholm on March 26, 2025. STOCKHOLM, March 27, 2025 /PRNewswire/ -- Shareholders and others had the opportunity to follow the Annual General Meeting live via Electrolux Group's website. A...
Keymed Biosciences Announces Annual Results of 2024
CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα...
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit...